Intellia Therapeutics (NASDAQ:NTLA) Releases Earnings Results, Hits Expectations

Intellia Therapeutics (NASDAQ:NTLA) announced its quarterly earnings data on Thursday. The company reported ($0.80) earnings per share for the quarter, meeting the consensus estimate of ($0.80), FiscalAI reports. Intellia Therapeutics had a negative net margin of 672.16% and a negative return on equity of 58.80%. The business had revenue of $7.66 million for the quarter, compared to analyst estimates of $12.98 million. During the same period in the prior year, the business posted ($0.98) earnings per share. Intellia Therapeutics’s revenue was down 46.4% compared to the same quarter last year.

Here are the key takeaways from Intellia Therapeutics’ conference call:

• Lonvo-z’s phase III HALO trial succeeded, showing an 87% reduction in mean monthly HAE attacks versus placebo, with 62% of patients attack-free and therapy-free during the six-month evaluation period. Intellia expects FDA acceptance of the rolling BLA by year-end and is preparing for a potential U.S. launch in the first half of 2027.
• Nex-z phase III enrollment and dosing resumed in both ATTR trials during the second quarter after clinical holds were resolved, with screening rates increasing globally. Intellia reported that MAGNITUDE has enrolled more than 650 patients and that blinded event rates remain within its internal projections.
• Intellia identified the HLA-C*05:01 allele as associated with a significantly higher rate of severe transaminase elevations following nex-z treatment. The allele is present in roughly 12% of patients, although most carriers did not experience severe elevations; updated protocols now require HLA typing and enhanced risk disclosure.
• The company ended June with $628.4 million in cash, equivalents, and marketable securities after raising approximately $195 million in net proceeds through an April equity financing. Management believes this provides a cash runway into at least 2028, excluding potential lonvo-z product revenue.
• Second-quarter collaboration revenue declined to $7.7 million from $14.2 million year over year, while net loss widened to $106.6 million from $101.3 million. R&D expenses fell, but G&A increased due to commercial infrastructure build-out, legal costs, and higher stock-based compensation.

Intellia Therapeutics Price Performance

NTLA traded up $0.70 during trading on Friday, reaching $11.94. The company had a trading volume of 4,923,615 shares, compared to its average volume of 4,163,880. The company has a market cap of $1.67 billion, a P/E ratio of -3.55 and a beta of 1.81. Intellia Therapeutics has a 12 month low of $7.95 and a 12 month high of $28.25. The business’s fifty day moving average price is $13.65 and its 200 day moving average price is $13.48.

Key Stories Impacting Intellia Therapeutics

Here are the key news stories impacting Intellia Therapeutics this week:

• Positive Sentiment: Evercore ISI upgraded Intellia Therapeutics, citing a favorable “nex-z hypothesis.” The upgrade suggests the firm sees greater potential in Intellia’s gene-editing pipeline, providing the clearest positive catalyst in the recent news flow. Intellia upgraded at Evercore ISI on nex-z hypothesis
• Positive Sentiment: Brookline Capital Markets raised its fourth-quarter 2026 EPS forecast to a loss of $0.41 from $0.47, while projecting a path to profitability beginning in 2027. That outlook supports the longer-term investment case, although the firm made broader reductions to its estimates. Brookline Capital Markets estimates
• Neutral Sentiment: Bank of America Securities maintained a Hold rating, indicating the firm sees neither a sufficiently strong near-term catalyst nor enough downside to change its stance. Bank of America Securities remains a Hold on Intellia Therapeutics
• Negative Sentiment: Intellia’s second-quarter loss was in line with expectations, but revenue fell about 46% year over year to $7.66 million, missing estimates of roughly $12.98 million. The decline was attributed to lower revenue from the Regeneron collaboration, highlighting the company’s reliance on partnership income while it continues to spend heavily on research and development. NTLA Q2 earnings in line, top line misses on lower Regeneron revenues
• Negative Sentiment: Brookline lowered its estimates for the second and third quarters of 2026 and reduced its full-year 2026 forecast to a $2.84 per-share loss. More significantly, projected EPS was cut for 2027 through 2030, including a reduction in 2030 estimates from $68.52 to $25.07, signaling lower expectations for the eventual commercial opportunity.
• Negative Sentiment: WallStreetZen downgraded NTLA to Strong Sell, adding to the bearish analyst commentary and reinforcing concerns about continued losses, execution risk and valuation. Intellia lowered to Strong Sell rating

Insider Buying and Selling at Intellia Therapeutics

In other news, CAO Michael P. Dube sold 2,641 shares of the stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $16.78, for a total transaction of $44,315.98. Following the completion of the sale, the chief accounting officer owned 66,886 shares of the company’s stock, valued at $1,122,347.08. This represents a 3.80% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, EVP Edward J. Dulac III sold 4,677 shares of the firm’s stock in a transaction on Thursday, July 2nd. The stock was sold at an average price of $18.00, for a total transaction of $84,186.00. Following the sale, the executive vice president owned 156,286 shares in the company, valued at approximately $2,813,148. The trade was a 2.91% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 3.50% of the stock is owned by corporate insiders.

Institutional Trading of Intellia Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. ARK Investment Management LLC boosted its holdings in Intellia Therapeutics by 19.2% during the fourth quarter. ARK Investment Management LLC now owns 14,207,324 shares of the company’s stock worth $127,724,000 after purchasing an additional 2,288,146 shares during the last quarter. State Street Corp increased its stake in Intellia Therapeutics by 29.1% in the 4th quarter. State Street Corp now owns 6,418,836 shares of the company’s stock valued at $57,705,000 after buying an additional 1,447,967 shares during the last quarter. Renaissance Technologies LLC increased its stake in Intellia Therapeutics by 156.9% in the 4th quarter. Renaissance Technologies LLC now owns 1,672,700 shares of the company’s stock valued at $15,038,000 after buying an additional 1,021,700 shares during the last quarter. HRT Financial LP bought a new stake in Intellia Therapeutics during the 4th quarter worth about $6,876,000. Finally, BNP Paribas Financial Markets lifted its position in Intellia Therapeutics by 1,076.6% during the 4th quarter. BNP Paribas Financial Markets now owns 591,277 shares of the company’s stock worth $5,316,000 after buying an additional 541,026 shares in the last quarter. Institutional investors and hedge funds own 88.77% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have commented on NTLA. Chardan Capital upped their target price on shares of Intellia Therapeutics from $27.00 to $30.00 and gave the company a “buy” rating in a research report on Monday, April 27th. Canaccord Genuity Group reissued a “buy” rating and issued a $49.00 price target on shares of Intellia Therapeutics in a research note on Tuesday, June 16th. Wedbush raised their price target on Intellia Therapeutics from $12.00 to $17.00 and gave the stock a “neutral” rating in a research report on Friday, July 10th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Intellia Therapeutics in a research note on Friday, July 17th. Finally, Wolfe Research downgraded Intellia Therapeutics from a “peer perform” rating to an “underperform” rating and set a $9.00 price objective for the company. in a report on Wednesday, July 15th. One investment analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, eight have given a Hold rating and four have given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $20.85.

About Intellia Therapeutics

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical?stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease?causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.